ZMYND11 and prostate carcinoma: Importantly, ZMYND11 was consistently downregulated in metastatic samples from several independent human prostate cancer clinical datasets41–44 (Fig. 1b and Supplementary Fig. 1b), and its downregulation was notably correlated with high Gleason scores, advanced tumor stages, and elevated prostate-specific antigen (PSA) levels45–47 (Fig. 1c and Supplementary Fig. 1c).